Literature DB >> 2660987

Immunology of gliomas.

N de Tribolet1.   

Abstract

The treatment of cerebral gliomas continues to challenge neurosurgeons and research scientists. The lack of major success with chemotherapy and radiation therapy has given rise to further investigation into the biology of these tumors and host reactions to them. Much of this research has centered upon the evaluation of tumor cell antigenicity and on both the humoral and cellular immune responses to gliomas. Contrary to previous considerations, evidence suggests that astrocytes, glioma cells, and tumor endothelial cells may all have pivotal roles in the initiation and prolongation of both local and systemic immune responses to the tumor. In this review we will discuss the immunobiology of the glioma with specific reference to the interactions between the tumor and the host immune system. In addition, ideas for potential therapeutic manipulation of the host-glioma immune interactions will be reviewed, stressing potential pitfalls and risks.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2660987     DOI: 10.1007/bf00571111

Source DB:  PubMed          Journal:  Childs Nerv Syst        ISSN: 0256-7040            Impact factor:   1.475


  48 in total

1.  Antigen presentation: comments on its regulation and mechanism.

Authors:  E R Unanue; D I Beller; C Y Lu; P M Allen
Journal:  J Immunol       Date:  1984-01       Impact factor: 5.422

2.  Letter: Impaired cell-mediated immunity in human brain tumours.

Authors:  D G Thomas; C B Lannigan; P O Behan
Journal:  Lancet       Date:  1975-06-21       Impact factor: 79.321

3.  Therapeutic potential for blood-brain barrier modification in malignant brain tumor.

Authors:  E A Neuwelt
Journal:  Prog Exp Tumor Res       Date:  1984

4.  Amplification, enhanced expression and possible rearrangement of EGF receptor gene in primary human brain tumours of glial origin.

Authors:  T A Libermann; H R Nusbaum; N Razon; R Kris; I Lax; H Soreq; N Whittle; M D Waterfield; A Ullrich; J Schlessinger
Journal:  Nature       Date:  1985 Jan 10-18       Impact factor: 49.962

5.  In vivo localisation of radiolabelled monoclonal antibody in human gliomas.

Authors:  J Behnke; J P Mach; F Buchegger; S Carrel; B Delaloye; N De Tribolet
Journal:  Br J Neurosurg       Date:  1988       Impact factor: 1.596

6.  Expression of HLA-DR and common acute lymphoblastic leukemia antigens on glioma cells.

Authors:  S Carrel; N De Tribolet; N Gross
Journal:  Eur J Immunol       Date:  1982-04       Impact factor: 5.532

7.  Common antigenic determinants on human melanoma, glioma, neuroblastoma, and sarcoma cells defined with monoclonal antibodies.

Authors:  R C Seeger; H M Rosenblatt; K Imai; S Ferrone
Journal:  Cancer Res       Date:  1981-07       Impact factor: 12.701

8.  Immunohistological diagnosis of central nervous system tumours using a monoclonal antibody panel.

Authors:  H B Coakham; J A Garson; P M Allan; E I Harper; B Brownell; J T Kemshead; E B Lane
Journal:  J Clin Pathol       Date:  1985-02       Impact factor: 3.411

9.  Presence of tumor-associated antigens in epidermal growth factor receptors from different human carcinomas.

Authors:  A Basu; U Murthy; U Rodeck; M Herlyn; L Mattes; M Das
Journal:  Cancer Res       Date:  1987-05-15       Impact factor: 12.701

10.  Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-beta gene family.

Authors:  R de Martin; B Haendler; R Hofer-Warbinek; H Gaugitsch; M Wrann; H Schlüsener; J M Seifert; S Bodmer; A Fontana; E Hofer
Journal:  EMBO J       Date:  1987-12-01       Impact factor: 11.598

View more
  1 in total

Review 1.  Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of pre-clinical and clinical investigations.

Authors:  R E Merchant; M D Ellison; H F Young
Journal:  J Neurooncol       Date:  1990-04       Impact factor: 4.130

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.